FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a specific variant III of the epidermal growth factor receptor (EGFRvIII), a chimeric antigen receptor (CAR) containing an EGFRvIII-binding domain, a transmembrane domain and an intracellular signaling domain, as well as a polynucleotide encoding it. Also disclosed is a vector, a cell containing the above-mentioned polynucleotide. The invention also relates to an immune cell containing the above-mentioned polynucleotide, a method for its preparation, as well as a pharmaceutical composition containing it.
EFFECT: invention makes it possible to effectively treat cancer.
17 cl, 9 dwg, 10 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO CONSTANT REGION OF β T-CELL RECEPTOR | 2015 |
|
RU2830064C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| NON-NATURAL NKG2D RECEPTORS WHICH DO NOT DIRECTLY TRANSMIT SIGNAL TO CELLS WITH WHICH THEY ARE BOUND | 2019 |
|
RU2832538C2 |
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
| T-CELLS WITH TWO CHIMERIC ANTIGEN RECEPTORS (CAR) | 2021 |
|
RU2839662C1 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| ISOLATED ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF CHIMERIC ANTIGEN RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR INCLUDING IT | 2019 |
|
RU2742000C2 |
| CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2841244C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| INDUCIBLE CHIMERIC CYTOKINE RECEPTORS | 2019 |
|
RU2826155C2 |
